sub:assertion {
  <http://purl.obolibrary.org/obo/DOID_0050425> bl:category bl:Disease .
  sub:association rdf:object <http://purl.obolibrary.org/obo/DOID_0050425> ;
    rdf:predicate bl:treats ;
    rdf:subject <https://identifiers.org/drugbank:DB00413> ;
    a rdf:Statement ;
    rdfs:label "mirapex r pramipexole dihydrochloride tablets are indicated for the treatment of the signs and symptoms of idiopathic parkinson s disease the effectiveness of mirapex tablets was demonstrated in randomized controlled trials in patients with early parkinson s disease who were not receiving concomitant levodopa therapy as well as in patients with advanced disease on concomitant levodopa see clinical studies mirapex tablets are indicated for the treatment of moderate to severe primary restless legs syndrome rls key diagnostic criteria for rls are an urge to move the legs usually accompanied or caused by uncomfortable and unpleasant leg sensations symptoms begin or worsen during periods of rest or inactivity such as lying or sitting symptoms are partially or totally relieved by movement such as walking or stretching at least as long as the activity continues and symptoms are worse or occur only in the evening or night difficulty falling asleep may frequently be associated with symptoms of rls" ;
    bl:association_type bl:ChemicalToDiseaseOrPhenotypicFeatureAssociation ;
    bl:provided_by <https://w3id.org/um/NeuroDKG> ;
    bl:relation schema:TreatmentIndication .
  <https://identifiers.org/drugbank:DB00413> bl:category bl:Drug .
}